Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study shows that many acne patients use topical steroids despite their association with various skin side effects, such as worsened acne, perioral dermatitis, and telangiectasias.

In this study, researchers developed a precise and rapid method for simultaneously analyzing minoxidil and finasteride in local therapeutic formulations, ensuring that the excipients did not interfere, making it suitable for routine quality control.

This study found that coadministering minoxidil with tretinoin cream increased minoxidil absorption nearly threefold in healthy males, attributed to increased stratum corneum permeability.

This study found that finasteride-loaded microemulsions using poloxamer 124 significantly enhanced skin penetration of the drug compared to a standard solution, primarily through targeting hair follicles via the transfollicular pathway, with intercluster, intercellular, and transcellular pathways contributing less.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.

This retrospective study conducted at two centers in west Mexico identified distinctive trichoscopic features in pediatric androgenetic alopecia, with 70% of patients being male and most showing vitamin D deficiency; topical minoxidil was effective and well-tolerated as a treatment.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.

In this study, 70% of female androgenetic alopecia patients who did not respond to standard minoxidil experienced clinical improvement after switching to a propylene glycol-free, witch hazel-based 5% minoxidil sulfate solution, with the treatment also being well-tolerated.

This study concluded that trichoscopy is an effective, non-invasive tool for diagnosing telogen effluvium, with significant differences in trichoscopic findings between frontal and occipital scalp regions, aiding in distinguishing it from androgenetic alopecia for early diagnosis.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study observed significant improvements in hair loss and hair density among adults using USPlus DERM Topical serum daily for 12 weeks, with 90.9% of participants noticing better hair loss/density and rating satisfaction at an average of 7.7 out of 10.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

This study found that photobiomodulation after septoplasty reduced pain and inflammatory response, leading to less pronounced changes in autonomic nervous system activity compared to patients who did not receive this treatment.

This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This case report suggests a possible association between long-term finasteride use for male pattern baldness and the development of cataracts and intraoperative floppy-iris syndrome in a patient.

This study suggests that hair removal lasers, potentially combined with topical minoxidil, may target and treat the underlying mechanisms of trichoepithelioma lesions effectively, though clinical trials are needed to verify this approach.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This study developed cilostazol-loaded formulations for nose-to-brain delivery, finding that these formulations improved cilostazol's bioavailability by enhancing solubility, absorption, and permeability, achieving nearly 100% drug release in vitro within 2 hours.

This study observed that patients using oral minoxidil for hair loss reported greater ease of use, fewer missed doses, and higher satisfaction compared to those using topical minoxidil, although oral minoxidil was associated with a higher incidence of hypertrichosis.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.

This review discusses recent therapeutic advances in treating various types of hair loss, including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and hair transplant technologies, but reports no new clinical results.

In this Stanford study, verteporfin was used to promote scarless skin regeneration by inhibiting YAP activity in a 27-year-old female, resulting in increased hair density at the treated site compared to the untreated control.

This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.